Theragenics reunites with Oncura in brachytherapy pact
This article was originally published in Clinica
Executive Summary
Brachytherapy specialist Theragenics has signed an exclusive agreement to provide Oncura with its TheraSeed palladium-103 seeds in the US and Canada. The deal will last until 31 May 2013 and has the option for additional one-year terms upon mutual agreement. Oncura will market TheraSeed, a therapy for prostate cancer, alongside its own products, the iodine-125-based OncoSeed and the RAPID Strand absorbable braided suture. The two firms previously had a similar agreement which ran from 2000-2005. When this contract finished, Buford, Georgia-based Theragenics said Oncura no longer shared its strategic objectives (www.clinica.co.uk, 17 December 2004). Since then, Oncura has become a subsidiary of GE Healthcare.